No connection

Search Results

ANIP vs INSP

ANIP
ANI Pharmaceuticals, Inc.
BEARISH
Price
$70.49
Market Cap
$1.58B
Sector
Healthcare
AI Confidence
85%
INSP
Inspire Medical Systems, Inc.
BULLISH
Price
$55.11
Market Cap
$1.59B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ANIP
21.23
INSP
11.27
Forward P/E
ANIP
6.82
INSP
21.32
P/B Ratio
ANIP
2.73
INSP
2.02
P/S Ratio
ANIP
1.79
INSP
1.74
EV/EBITDA
ANIP
10.33
INSP
20.02

Profitability

Gross Margin
ANIP
61.36%
INSP
85.39%
Operating Margin
ANIP
11.99%
INSP
17.14%
Profit Margin
ANIP
8.87%
INSP
15.95%
ROE
ANIP
16.16%
INSP
19.77%
ROA
ANIP
3.82%
INSP
3.71%

Growth

Revenue Growth
ANIP
29.6%
INSP
12.2%
Earnings Growth
ANIP
--
INSP
308.4%

Financial Health

Debt/Equity
ANIP
1.16
INSP
0.04
Current Ratio
ANIP
2.71
INSP
6.08
Quick Ratio
ANIP
2.07
INSP
4.46

Dividends

Dividend Yield
ANIP
--
INSP
--
Payout Ratio
ANIP
0.0%
INSP
0.0%

AI Verdict

ANIP BEARISH

ANIP's Piotroski F-Score of 4/9 indicates weak financial health, falling short of the stable threshold and signaling potential operational inefficiencies. The absence of an Altman Z-Score raises concern about bankruptcy risk, especially given a high debt/equity ratio of 1.16. Despite strong revenue growth (29.6% YoY) and solid gross margins (61.36%), the stock trades at a premium to its intrinsic value, with a current price of $70.49 versus a Graham Number of $43.90 and intrinsic value of $23.24. Insider selling activity totaling $3.39M in the last six months further undermines confidence, while technical trends remain bearish. Analysts remain optimistic with a $110.62 target, but this may reflect overvaluation given the underlying financial and sentiment risks.

Strengths
Strong revenue growth of 29.6% YoY
High gross margin of 61.36%
Solid operating margin of 11.99%
Risks
Piotroski F-Score of 4/9 indicates weak financial health
No Altman Z-Score available, raising potential bankruptcy risk
Insider selling activity totaling $3.39M in last 6 months
INSP BULLISH

INSP exhibits strong fundamental health with a Piotroski F-Score of 7/9 and an exceptionally clean balance sheet (Debt/Equity 0.04). While the stock has suffered a severe multi-year price collapse, it is currently trading almost exactly at its Graham Number ($54.84), suggesting it has reached a defensive valuation floor. The massive disconnect between the current price ($55.11) and the growth-based intrinsic value ($144.25), coupled with explosive earnings growth (308.4% YoY), presents a compelling value-growth opportunity. Despite bearish technicals and insider selling, the underlying profitability and liquidity metrics are superior to sector averages.

Strengths
Strong financial health indicated by Piotroski F-Score of 7/9
Exceptional gross margins (85.39%) and healthy ROE (19.77%)
Negligible debt levels (Debt/Equity 0.04) and high liquidity (Current Ratio 6.08)
Risks
Severe long-term price deterioration (5Y Change: -77.1%)
Bearish insider sentiment with recent selling activity
Strongly bearish technical trend (0/100 score)

Compare Another Pair

ANIP vs INSP: Head-to-Head Comparison

This page compares ANI Pharmaceuticals, Inc. (ANIP) and Inspire Medical Systems, Inc. (INSP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile